Canaan Partners Biotech Portfolio 2026

3 Biotech companies backed by Canaan Partners, including Draig Therapeutics, Normunity, Qlaris Bio — with the co-investors on each cap table.

Canaan Partners — Biotech accounts for 7 tracked companies with verified cap-table data, 7 of which disclose round sizes totalling $1.5B. The median disclosed raise is $202M, and the largest is EndoGastric Solutions at $374M, ahead of Catalym ($319M) and Alterome Therapeutics ($231M).

The names that recur most often on these portfolio cap tables are Canaan Partners (7 companies), Access Biotechnology (2 companies), Access Industries (2 companies), Accelmed (1 company), Advanced Technology Ventures (1 company), CRG (1 company). By latest disclosed round, the market skews Series A (3), Series I (1), Series D (1), Series B (1).

Best funded Canaan Partners — Biotech companies

  1. EndoGastric Solutions — $374M (latest: Series I)
  2. Catalym — $319M (latest: Series D)
  3. Alterome Therapeutics — $231M (latest: Series A)
  4. Halda Therapeutics — $202M (latest: Series B)
  5. Draig Therapeutics — $140M (latest: Series A)
  6. CytomX Therapeutics — $136M (latest: IPO)
  7. Vima Therapeutics — $100M (latest: Series A)

Canaan Partners Israel — related firms and companies (46)

Canaan Partners Israel profile · All research reports